TABLE 4.
HPV DNA prevalence for multiple infections in women with ASC-US and controls across TS-MPG and LA assays
| No. of infectionsa | HPV DNA prevalence |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ASC-US patients (n = 91) |
Controls (n = 84) |
|||||||||
| TS-MPG |
LA |
Pb | TS-MPG |
LA |
Pb | |||||
| No. | % | No. | % | No. | % | No. | % | |||
| 0 | 49 | 53.9 | 58 | 63.7 | 57 | 67.9 | 75 | 89.3 | ||
| 1 | 19 | 20.9 | 16 | 17.6 | 16 | 19.1 | 6 | 7.1 | ||
| 2 | 20 | 22.0 | 14 | 15.4 | 7 | 8.3 | 3 | 3.6 | ||
| ≥3 | 3 | 3.3 | 3 | 3.3 | <.0001 | 4 | 4.8 | 0 | 0.0 | <.0001 |
a
Prevalence of DNA positivity for HPV types included in both TS-MPG and LA assays.
b
Fisher's exact P value.